Dr. Larson Ode – Page 3

December 10, 2019January 11, 2022

Dr. Larson Ode to Help Mentor Faculty Across the Country.

There is a strong need to train endocrinologist to help provide expert care for the endocrine complications experienced by patients with cystic fibrosis. For this reason, the Cystic Fibrosis Foundation has established a program to identify national leaders in this area who can help mentor other endocrinologists. We are proud of Dr. Katie Larson Ode, who has been named one of the selected mentors to help train the future leaders in cystic fibrosis endocrinology. This honor includes grant funds to support her time in these efforts.

September 2, 2019January 11, 2022

Dr. Larson Ode Heads Multicenter Research Study.

Dr. Larson Ode is the principal investigator and leader of an ongoing multicenter research study aimed at better understanding cystic fibrosis related diabetes. The study is funded by the Cystic Fibrosis Foundation (https://www.cff.org/). The name of the study is the “EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis”, and will be funded at least through August 2021. As the leader of the study, Dr. Larson Ode coordinates studies at the University of Iowa, the University of Minnesota, University of Colorado, and Washington University in St Louis.

June 6, 2019January 11, 2022

Dr. Larson Ode Gives Invited European Lecture.

We are proud of Dr. Katie Larson Ode, who is giving an invited lecture today at the European Cystic Fibrosis Society annual Conference in Liverpool, UK. The title of her lecture as “CFRD (cystic fibrosis related diabetes) in the age of correctors”. Dr. Larson Ode is an internationally recognized expert in the care of patients with CFRD. Patients with cystic fibrosis are now being treated with powerful medications that directly restore function of the defective protein that causes their disease. These medications dramatically improve lung function, but their impact on cystic fibrosis related diabetes is less clear. In her talk, Dr. Larson Ode will review available data and discuss ongoing uncertainties.